Stockscreener 앱 받기
14.18
2.21%
-0.32
전일 마감가:
$14.50
열려 있는:
$14.12
하루 거래량:
278.05K
Relative Volume:
0.56
시가총액:
$807.68M
수익:
-
순이익/손실:
-
주가수익비율:
-
EPS:
-
순현금흐름:
-
1주 성능:
-4.25%
1개월 성능:
+34.15%
6개월 성능:
-43.71%
1년 성능:
+0.00%
1일 변동 폭
$13.76
$14.38
1주일 범위
$13.28
$15.61
52주 변동 폭
$8.91
$28.09
Bicara Therapeutics Inc Stock (BCAX) Company Profile
명칭
Bicara Therapeutics Inc
전화
617-785-8308
주소
245 MAIN STREET, CAMBRIDGE
BCAX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
BCAX
Bicara Therapeutics Inc
|
14.18 | 807.68M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
502.70 | 127.64B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
605.03 | 65.95B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
655.56 | 37.92B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
268.17 | 32.98B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
254.08 | 26.89B | 3.81B | -644.79M | -669.77M | -6.24 |
Bicara Therapeutics Inc Stock (BCAX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-04-17 | 개시 | Wells Fargo | Underweight |
| 2025-02-06 | 개시 | Wedbush | Outperform |
| 2024-12-06 | 개시 | H.C. Wainwright | Buy |
| 2024-11-05 | 개시 | Rodman & Renshaw | Buy |
| 2024-10-08 | 개시 | Cantor Fitzgerald | Overweight |
| 2024-10-08 | 개시 | Morgan Stanley | Overweight |
| 2024-10-08 | 개시 | Stifel | Buy |
| 2024-10-08 | 개시 | TD Cowen | Buy |
모두보기
Bicara Therapeutics Inc 주식(BCAX)의 최신 뉴스
Analysts Set Bicara Therapeutics Inc. (NASDAQ:BCAX) PT at $32.43 - Defense World
A new trading data show Bicara Therapeutics Inc (BCAX) is showing positive returns. - Sete News
Legal & General Group Plc Acquires New Holdings in Bicara Therapeutics Inc. (NASDAQ:BCAX) - Defense World
Bicara Therapeutics Inc [BCAX] Shares Fall -3.43 % on Wednesday - knoxdaily.com
A closer look at Bicara Therapeutics Inc (BCAX)’s stock price trends - uspostnews.com
Wedbush Lifts Earnings Estimates for Bicara Therapeutics - Defense World
Promising Potential of Bicara Therapeutics’ Ficerafusp Alfa Drives Buy Rating Amid Encouraging Clinical Data and Growth Opportunities - TipRanks
Cautious Outlook on Bicara Therapeutics Inc. Amid Efficacy and Safety Concerns for Ficerafusp - TipRanks
Promising Clinical Trial Results Boost Buy Rating for Bicara Therapeutics - TipRanks
Bicara Therapeutics Highlights Broad Potential of Ficerafusp Alfa at AACR Annual Meeting 2025 - GlobeNewswire
Riding the Waves: A Guide to Investing in BCAX Stock - investchronicle.com
JPMorgan Chase & Co. Buys 64,010 Shares of Bicara Therapeutics Inc. (NASDAQ:BCAX) - Defense World
Bicara Therapeutics (NASDAQ:BCAX) Shares Gap Down – Here’s Why - Defense World
Bicara Therapeutics Inc: Navigating Market Volatility with a 1.79 Debt-to-Equity Ratio - investchronicle.com
Bicara Therapeutics Inc (NASDAQ: BCAX) Is The Among Hot Stock Right Now - Stocksregister
Geode Capital Management LLC Acquires 418,003 Shares of Bicara Therapeutics Inc. (NASDAQ:BCAX) - Defense World
Bicara to present updated trial data at ASCO Meeting - Investing.com
Bicara to present updated trial data at ASCO Meeting By Investing.com - Investing.com South Africa
Bicara Therapeutics to Present Updated Data from Ongoing Phase 1/1b Trial of Ficerafusp alfa in 1L R/M HNSCC at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting - The Manila Times
Bicara Therapeutics to Present Updated Phase 1/1b Clinical Trial Data for Ficerafusp Alfa at ASCO 2025 - Nasdaq
Bicara Stock: Innovative Precision Tumor Targeting (NASDAQ:BCAX) - Seeking Alpha
Wells Fargo & Company Initiates Coverage on Bicara Therapeutics (NASDAQ:BCAX) - Defense World
Wells Fargo Initiates Coverage of Bicara Therapeutics (BCAX) with Underweight Recommendation - MSN
Vanguard Group Inc. Acquires 1,020,528 Shares of Bicara Therapeutics Inc. (NASDAQ:BCAX) - Defense World
Bicara Therapeutics initiated with an Underweight at Wells Fargo - TipRanks
This Twin Disc Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday - Benzinga
Wells Fargo Initiates Bicara Therapeutics at Underweight With $8 Price Target - marketscreener.com
Corebridge Financial Inc. Takes $167,000 Position in Bicara Therapeutics Inc. (NASDAQ:BCAX) - Defense World
HC Wainwright Issues Pessimistic Forecast for BCAX Earnings - Defense World
Promising Developments and Market Opportunities Drive Buy Rating for Bicara Therapeutics - TipRanks
HC Wainwright Issues Pessimistic Forecast for Bicara Therapeutics (NASDAQ:BCAX) Stock Price - The AM Reporter
Bicara Therapeutics Inc. (NASDAQ:BCAX) Receives $36.67 Average Target Price from Brokerages - Defense World
Bicara Therapeutics (NASDAQ:BCAX) Given New $44.00 Price Target at HC Wainwright - Defense World
Bicara stock price target lowered to $44 at H.C. Wainwright By Investing.com - Investing.com Canada
Bicara stock price target lowered to $44 at H.C. Wainwright - Investing.com
Buy Rating Affirmed for Bicara Therapeutics Inc. Amid Promising Clinical Data and Financial Stability - TipRanks
Bicara Therapeutics (NASDAQ:BCAX) Stock Price Down 3.2%Should You Sell? - MarketBeat
FY2025 EPS Estimates for BCAX Raised by Cantor Fitzgerald - Defense World
Cantor Fitzgerald maintains Overweight on Bicara Therapeutics stock - Investing.com
Cantor Fitzgerald maintains Overweight on Bicara Therapeutics stock By Investing.com - Investing.com UK
Promising Data and Durable Responses Drive Buy Rating for Bicara Therapeutics - TipRanks
Q1 EPS Estimate for Bicara Therapeutics Reduced by Analyst - Defense World
Bicara Therapeutics (NASDAQ:BCAX) Earns Outperform Rating from Wedbush - Defense World
Charles Schwab Investment Management Inc. Takes Position in Bicara Therapeutics Inc. (NASDAQ:BCAX) - Defense World
Stifel raises Bicara stock price target to $48, maintains Buy By Investing.com - Investing.com Canada
Buy Rating for Bicara Therapeutics Inc. Driven by Promising Clinical Progress and Strong Financial Position - TipRanks
Bicara Therapeutics Reports Strong Financial Position and Clinical Progress - TipRanks
Analysts Adjust Price Targets For Nkarta And Bicara - Evrim Ağacı
Stifel raises Bicara stock price target to $48, maintains Buy - Investing.com India
Bank of New York Mellon Corp Makes New Investment in Bicara Therapeutics Inc. (NASDAQ:BCAX) - Defense World
Bicara Therapeutics Inc (BCAX) 재무 분석
Bicara Therapeutics Inc (BCAX)에 대한 금융 데이터가 없습니다. 더 많은 정보를 위해 다른 주식을 확인해보세요.
매출
순이익
현금흐름
주당 순 이익
Bicara Therapeutics Inc 주식 (BCAX) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Meisner Lara | Chief Legal Officer |
Mar 14 '25 |
Sale |
12.90 |
79,146 |
1,021,211 |
0 |
0.03%
0.49%
자본화:
|
볼륨(24시간):